News | October 11, 2023
AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Marks the World Head & Neck Cancer Day at the OCTF Conference
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being
Subscribe To Our Newsletter & Stay Updated
